Buy GHK-Cu, 60 mg

€27.82

GHK-Cu, 60 mg, is a copper(II) glycyl-His-Lys complex for coordination chemistry, peptide analytics and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to lot-specific copper, purity and identity verification.

Category:
Description

Buy GHK-Cu, 60 mg, for Advanced Laboratory Research in Europe

GHK-Cu is a copper(II) coordination complex of the tripeptide glycyl-L-histidyl-L-lysine, commonly written Gly-His-Lys–Cu(II). It is supplied as a laboratory reagent for coordination chemistry, peptide analytics, metal–ligand studies and controlled in vitro investigations. The complex is frequently reported near 402–403 Da, although the stated formula and mass depend on how copper coordination, charge and hydration are represented. Pharma Research .eu presents this 60 mg format for qualified European laboratory teams.pubchem.ncbi.nlm.nih+2

Uncompromising Purity and Analytical Characterisation

GHK-Cu should be distinguished clearly from free GHK. The copper-free tripeptide is commonly designated Gly-His-Lys and has a reported molecular mass of approximately 340.38 Da. GHK-Cu contains a coordinated copper(II) ion and is a chemically distinct complex with different mass, charge, spectroscopy and metal-binding behaviour.uk-peptides+1

For procurement, the appropriate target is ≥99.0% purity by RP-HPLC for the peptide-related component, together with independent confirmation of copper content and complex identity. HPLC alone may not fully characterise a metal–peptide complex, so the analytical package should ideally combine chromatography with mass spectrometry and an orthogonal copper assay.

A complete CoA should include:

  • RP-HPLC purity percentage and chromatogram.

  • LC-MS, ESI-MS or high-resolution MS identity confirmation.

  • Copper-content or elemental analysis.

  • Peptide sequence and stereochemical designation.

  • Copper-to-peptide stoichiometry, preferably demonstrating a 1:1 complex.

  • Formula and molecular mass for the supplied ionic or salt form.

  • Visual appearance of the lyophilised material.

  • Residual-solvent results from synthesis and purification.

  • Water or residual-moisture content, where measured.

  • Heavy-metal and elemental-impurity results, including non-copper metals where tested.

  • Lot number, manufacture date, retest date and storage requirements.

Public references report several representations of GHK-Cu, including C₁₄H₂₂CuN₆O₄, C₁₄H₂₃CuN₆O₄⁺ and related charged or hydrated forms. Reported average molecular masses range from approximately 400.9 to 403.9 g/mol. These are not necessarily contradictory if they refer to different charge, hydration or salt conventions, but the supplier must state which form is actually supplied.pubchem.ncbi.nlm.nih+3

GHK-Cu is generally supplied as a blue to blue-green, turquoise or blue-purple lyophilised solid, although the exact appearance depends on concentration, drying process, counter-ions and residual moisture. The colour may reflect copper coordination, but it is not proof of identity or purity. Analytical release should combine appearance assessment with RP-HPLC, mass spectrometry and copper-content testing.

Purity is non-negotiable for reproducible work because free GHK, unbound copper, copper hydrolysis products, peptide truncations and other metal complexes can produce different chemical and biological responses. A nominally high-purity peptide without confirmed copper stoichiometry may not be equivalent to a characterised GHK-Cu complex. Lower-grade material can compromise metal–ligand studies, spectroscopy, cellular assays and quantitative LC-MS.

Any bacteriostatic-water or other aqueous component should be documented separately. Preservatives and ions in the diluent may disturb copper–ligand equilibria, alter pH or affect cellular and analytical assays.

Principal Laboratory Applications and Research Methodologies

GHK-Cu is suitable for controlled laboratory research involving coordination chemistry, copper–peptide interactions, analytical characterisation and in vitro model development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.

Metal–ligand coordination studies. GHK-Cu can be used to investigate copper binding, ligand stoichiometry, pH dependence and competition with other ligands. Suitable methods may include UV–visible spectroscopy, circular dichroism, mass spectrometry, ion chromatography or elemental analysis. Researchers should control pH, ionic strength, buffer identity and free-copper background.

RP-HPLC and LC-MS characterisation. The complex may support retention-time assignment, peptide-content analysis and detection of free GHK, unbound copper and related peptide species. Because metal binding can alter ionisation and chromatographic behaviour, the method should be validated with appropriate metal-free and copper-containing controls.

In vitro biochemical assays. A verified GHK-Cu lot may be incorporated into cell-free or cellular systems examining copper-dependent redox chemistry, extracellular-matrix-associated pathways or metal–peptide interactions. Assays should include free GHK, copper-only and vehicle controls where mechanistically relevant, so that observed effects can be attributed to the complex rather than to an unbound component.

Formulation and stability studies. Laboratories may examine the influence of pH, light, temperature, oxygen, chelating agents and competing anions on complex integrity. Stability-indicating methods should monitor both the peptide and copper content, because a solution can retain peptide-related HPLC signal while losing the intended coordination state.

The 60 mg quantity corresponds to approximately 149 µmol if calculated using 401.9 g/mol, or approximately 176 µmol if calculated using the copper-free GHK mass of 340.38 g/mol. These values demonstrate why the supplied chemical form must be confirmed before converting mass to molar concentration. No final solution concentration should be stated without the reconstitution volume, formula, purity and hydration state.

Bacteriostatic water should not automatically be assumed compatible with GHK-Cu. Preservatives, pH and trace chelators or competing ions may influence complex stability. Laboratories should validate the chosen diluent using copper-content, spectroscopic or chromatographic controls.

Compound Stability, Optimal Storage, and Safe Handling Protocols

Lyophilised GHK-Cu should generally be sealed, dry, protected from light and stored at approximately −20°C unless the lot-specific CoA specifies otherwise. Research references describe low-temperature, moisture-protected storage as important for preserving both peptide integrity and the intended metal–ligand state.americanpeptides+2

Recommended controls include:

  • Store unopened lyophilised GHK-Cu at −20°C unless the CoA specifies another condition.

  • Consider −80°C for extended archival storage where supported by the stability programme.

  • Protect the material from light, moisture and unnecessary oxygen exposure.

  • Allow a sealed vial to reach room temperature before opening to reduce condensation.

  • Use low-binding, metal-compatible containers where adsorption or metal contamination could affect recovery.

  • Prepare aliquots if repeated access is expected.

  • Store short-term aqueous solutions at 2–8°C only where validated.

  • Avoid repeated freeze–thaw cycles.

  • Avoid unvalidated chelating agents, strongly alkaline conditions and buffers known to bind copper.

  • Record solvent, pH, concentration, preparation date, operator and storage history.

Solution stability is formulation-dependent. Copper can exchange ligands, hydrolyse or bind to container surfaces, buffers and contaminants. A clear or coloured solution should not be assumed to retain the original 1:1 complex. Stability studies should monitor peptide concentration, copper content and, where relevant, spectroscopic signatures of coordination.

Reconstitution should be performed using a validated laboratory procedure. Add the selected aqueous reagent gradually and mix gently. Avoid vigorous agitation and avoid introducing metal-containing tools or contaminated buffers. If precipitation, unexpected colour change or persistent turbidity occurs, the material should be investigated analytically before use.

Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and contact with the powder or solution. Dispose of copper-containing and peptide-containing waste according to approved institutional chemical-waste procedures.

Technical Specifications and Molecular Attributes

Attribute Specification
Product GHK-Cu, 60 mg
Common designation Copper tripeptide; copper(II) glycyl-L-histidyl-L-lysinate
Peptide sequence Gly-His-Lys
Residue count 3 amino acids plus coordinated Cu(II)
IUPAC name Copper(II) glycyl-L-histidyl-L-lysinate; confirm ionic form and stereochemistry on the CoA
CAS Registry Number 89030-95-5 is widely reported; verify the exact supplied form
Molecular formula Commonly reported as C₁₄H₂₂CuN₆O₄ or a charged equivalent; confirm on the CoA
Average molecular mass Approximately 401.9–403.9 g/mol depending on ionic, hydrated or salt representation
Physical state and colour Typically blue to blue-green lyophilised solid; verify against the batch specification
Solubility profile Generally aqueous-compatible, but pH, buffer, chelators and competing ligands require validation
Typical purity Proposed target ≥99.0% peptide-related purity by RP-HPLC plus copper-content verification
Identity testing LC-MS, RP-HPLC and elemental or copper assay
Long-term storage Typically −20°C, sealed, dry and protected from light

The distinction between free GHK and GHK-Cu is essential: free GHK is commonly reported at approximately 340.38 g/mol, whereas the copper complex is generally reported near 402–403 g/mol. The final product specification must identify the copper stoichiometry and ionic form.artemispeptides+3

Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents

Pharma Research .eu can position GHK-Cu as a documented European coordination-chemistry and peptide research reagent for analytical chemists, biochemists and laboratory managers. The product file should include a batch-specific CoA, SDS, peptide sequence, copper-content result, complex stoichiometry, purity result, identity data, formula, molecular mass and storage instructions.

Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.

A quality-focused supplier should be able to discuss:

  • Free GHK versus the GHK-Cu complex.

  • Copper stoichiometry and ionic form.

  • RP-HPLC purity and LC-MS identity testing.

  • Copper and elemental-impurity analysis.

  • Residual solvents, moisture and container compatibility.

  • Buffer, chelator and reconstitution compatibility.

  • Storage, transport and documentation requirements.

Pharma Research .eu should therefore be described as a potential European source for research-grade GHK-Cu, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy GHK-Cu, 60 mg”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

MAECENAS IACULIS

Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.

ADIPISCING CONVALLIS BULUM

  • Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
  • Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
  • Diam parturient dictumst parturient scelerisque nibh lectus.

Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.